CEOs are known for giving rosy outlooks for the future. And when that doesn't happen, it should raise some serious red flags. Recently, Moderna (NASDAQ: MRNA)'s CEO highlighted a big risk for the company: Demand for its COVID-19 vaccine is going to crater. It's a big enough decline to get investors worried.

Moderna is anticipating a big drop in demand this year as concerns around COVID-19 subside. It's a big reason why the healthcare stock trades at a lowly eight times earnings -- investors know that earnings will take a hit this year. One way Moderna plans to offset some of the decline in demand is by raising the price of its vaccine to $130 per dose. Previously, the company was selling its doses for less than $30 to the U.S. government.

The purchases will now come from the private sector, and so volumes will be lower. But just how much lower is what might surprise investors. "We're expecting a 90% reduction in demand" is what CEO Stéphane Bancel told U.S. senators at a hearing this month to defend the company's price hike.

Continue reading

Source Fool.com